The onset of heart failure is typically preceded by cardiac hypertrophy, a response of the
heart to increased workload, a cardiac insult such as a heart attack or genetic mutation …

Heart failure is a global problem with an estimated prevalence of 38 million patients
worldwide, a number that is increasing with the ageing of the population. It is the most …

Administration of mesenchymal stem cells (MSCs) to diseased hearts improves cardiac
function and reduces scar. These effects occur via stimulation of endogenous repair …

Summary Background Sarcoplasmic/endoplasmic reticulum Ca 2+-ATPase (SERCA2a)
activity is deficient in the failing heart. Correction of this abnormality by gene transfer might …

The mammalian heart is responsible for not only pumping blood throughout the body but
also adjusting this pumping activity quickly depending upon sudden changes in the …

Background—Adeno-associated virus type 1/sarcoplasmic reticulum Ca2+-ATPase was
assessed in a randomized, double-blind, placebo-controlled, phase 2 study in patients with …

Heart disease remains the leading cause of death and disability in the Western world.
Current therapies aim at treating the symptoms rather than the subcellular mechanisms …

Rationale: The Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In
Cardiac Disease (CUPID 1) study was a phase 1/phase 2 first-in-human clinical gene …

BACKGROUND: SERCA2a deficiency is commonly seen in advanced heart failure (HF).
This study is designed to investigate safety and biological effects of enzyme replacement …

Adeno-associated virus (AAV) based vectors have emerged as important tools for gene
therapy in humans. The recent successes seen in Phase I/II clinical trials have also …